• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Drug Development - Articles and news items

How the implementation of Exalt™ for evaporative crystallisation studies improves stability and controlled delivery in drug development.

How the implementation of Exalt™ for evaporative crystallisation studies improves stability and controlled delivery in drug development.

Supplier news / 12 July 2016 / Biopharma Group

Polymorph screening is an important stage of drug development. The aim is to identify the different crystalline structures or polymorphs that a drug may appropriate…

Coulter Partners

Coulter Partners has placed Dr Neil Brewis as Chief Scientific Officer and Michael Davies as VP Protein Science at F-star

Supplier news / 6 April 2016 / Coulter Partners

Coulter Partners has placed Dr Neil Brewis as Chief Scientific Officer and Michael Davies as VP Protein Science at F-star…

Future proofing - Part 2. PAT – Real Time Release Testing of Tablets

Future proofing – Part 2. PAT – Real time release testing of tablets

Supplier news / 4 April 2016 / Charles Ischi AG | Kraemer Elektronik

What requirements need to be met by a tablet testing system to guarantee a successful product release?

DiscoverX Corporation logo - 200

DiscoverX launches KILR™ assay platform for use in cancer immunotherapy drug development

Supplier news / 30 March 2016 / DiscoverX Corporation

DiscoverX Corporation has launched the KILR Retroparticles product line, providing scientists complete flexibility to develop a simple cytotoxicity assay in almost any cell line…

Future proofing - Part 1. Modularity and flexibility New LAB.line Tablet Hardness Testers

Future proofing – Part 1. Modularity and flexibility – New LAB.line tablet hardness testers

Supplier news / 29 February 2016 / Arwid Ischi, Charles Ischi AG | Kraemer Elektronik

What requirements need to be met by a tablet testing system to guarantee a successful product release? Is it dependable upon the testing system’s quality, speed, technology, flexibility or safety? Kraemer and Ischi explain…

High Pressure Homogenisation & the next generation of drug delivery: Liposomes

High Pressure Homogenisation & the next generation of drug delivery: Liposomes

Supplier news / 24 February 2016 / Biopharma Group

Liposomes are valued delivery vehicles for potent and efficacious active pharmaceuticals…

inABLE® technology helps unlock the secrets of cyclic peptides

inABLE® technology helps unlock the secrets of cyclic peptides

Supplier news / 17 February 2016 / Ingenza Laboratory

Ingenza is using its proprietary inABLE® technology to help develop a robust, versatile platform for the production of cyclic peptides for therapeutic use…

Quotient Clinical

Quotient Clinical celebrates its 100th RapidFACT® program

Supplier news / 11 February 2016 / Quotient Clinical

Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has completed its 100th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the growth of this service, which addresses drug R&D productivity issues…

Quotient Clinical

Quotient Clinical expands its formulation development services with the acquisition of Co-Formulate

Supplier news / 16 December 2015 / Quotient Clinical

Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has acquired formulation development specialist Co-Formulate Limited…

Quotient Clinical

Quotient Clinical’s Chief Scientific Officer awarded honorary professorship at the University of Nottingham

Supplier news / 12 August 2015 / Quotient Clinical

Quotient Clinical, the Translational Pharmaceutics® Company, has announced that Dr Peter Scholes, its Chief Scientific Officer, has been awarded an honorary professorship in the School of Pharmacy at the University of Nottingham…

mayor

Mayor of London considers £10bn ‘megafund’ as option to boost drug development

Industry news / 25 June 2015 / Victoria White

Plans to create a £10bn megafund that would make it easier for drug development will be discussed at a conference hosted by the Mayor of London’s Office…

Quotient Clinical

Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics

Supplier news / 10 June 2015 / kdm communications

Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +